Few areas of medicine swing harder between hype and fear. The truth is quieter: hormones are one system among several — measurable, sometimes worth treating, never a shortcut.
What actually declines
Testosterone falls gradually in men — roughly 1% a year from the mid-thirties — but symptomatic deficiency is about the combination of low values and real symptoms: low drive, flat mood, poor recovery, strength loss. Numbers without symptoms rarely justify treatment; symptoms without numbers deserve a search for other causes first (sleep, depression, medications, metabolic disease).
For women, perimenopause is less a decline than a turbulence: estrogen and progesterone swing before they settle. The symptom load — sleep disruption, vasomotor symptoms, mood, bone loss — is real and treatable, and modern evidence supports hormone therapy for many women within roughly ten years of menopause, individualized for risk.
Before anyone writes a prescription
- Two morning measurements, properly timed — hormones fluctuate too much for one draw to decide anything.
- The full context: thyroid, prolactin, SHBG, metabolic panel, sleep quality, training load.
- Fix the free lever first: sleep restriction and untreated apnea suppress testosterone as much as a decade of aging.
- A real risk conversation — fertility, hematocrit, cardiovascular context — and a monitoring plan.
Hormone optimization at LUMA means treating a diagnosed deficiency with the lowest effective dose, re-testing on schedule, and being equally willing to stop as to start. The goal is how you feel and function — the number is just the map.
Key references: TRAVERSE trial (testosterone CV safety, NEJM 2023); Menopause Society position statements 2022; Endocrine Society guidelines. Concept brand — not medical advice; hormone therapy requires individualized clinical care.
